

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Status Change Notice – April 18, 2007

NOTICE OF STATUS CHANGE

This study will reopen to the accrual of 3 additional patients at dose level 0 effective Wednesday, April 18, 2007.

Please retain this notice with the protocol.